鲁抗医药（600789）公告，预计2025年半年度实现归属于母公司所有者的净利润1.02亿元-1.22亿元。与 上年同期相比，将减少1.78亿元-1.98亿元，同比减少59.34%-65.98%。预计2025年半年度实现归属于母 公司所有者的扣除非经常性损益的净利润9488万元-1.08亿元。与上年同期相比，将增加320万元-1600万 元，同比增加3.49%-17.45%。 ...

Core Viewpoint - The collaboration between Qingdao Institute of Bioenergy and Process Research and Shandong Lukang Pharmaceutical has successfully developed a microbial green manufacturing technology for trans-aconitic acid, overcoming production challenges and achieving large-scale production, which has been recognized with a first-class award in Shandong Province for 2024 [1][3][12] Group 1: Production Challenges and Solutions - Trans-aconitic acid is a food additive with significant applications in agriculture, medicine, and chemicals, but traditional production methods face high costs and inefficiencies [3][9] - The research team developed an integrated technology system using industrial Aspergillus niger as a chassis cell, enabling the conversion of starch sugars into trans-aconitic acid through synthetic biology [3][5] - Key challenges addressed include the genetic modification of industrial strains, achieving high-efficiency synthesis, and optimizing fermentation processes for industrial application [5][7] Group 2: Industrial Application and Market Potential - The successful production of trans-aconitic acid opens up new avenues for its use as a biopesticide, particularly in combating root-knot nematodes in agriculture, aligning with national green agriculture initiatives [9][11] - In the chemical industry, trans-aconitic acid is being developed into a bio-based plasticizer, providing a safer alternative to petroleum-based phthalate plasticizers, which are facing regulatory restrictions due to health concerns [11][12] - The technology has garnered attention from various enterprises, leading to successful production demonstrations and positioning trans-aconitic acid as a key bio-based chemical in the upcoming 2024-2027 development plan for fine chemical industries [12]

Investment Rating - The report indicates a positive outlook for the pharmaceutical and biotechnology sector, with a focus on innovative drug companies [2][3]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.82%, outperforming the CSI 300 index (0.82%) and the Wind All A index (1.71%). The market is currently focused on the expectations surrounding semi-annual reports and business development (BD) activities [8][9]. - The launch of the 2025 National Basic Medical Insurance and Commercial Health Insurance innovative drug directory is a significant development. This directory will include high-innovation drugs that provide substantial clinical value and patient benefits, which are not covered by basic medical insurance but recommended for commercial health insurance [3][13]. - The report highlights the importance of the commercial health insurance sector in the payment for innovative drugs, suggesting that the accessibility of high-priced innovative drugs is expected to improve, particularly in the areas of cell and gene therapy [3][13]. Market Weekly Review - The medical research outsourcing sector led the gains with a 9.29% increase, primarily driven by WuXi AppTec's positive semi-annual report announcement. Conversely, offline pharmacies and other biological products experienced declines of -1.29% and -1.55%, respectively [8][9]. - Notable stock performances included Frontier Biotech-U (41.4%), Mediso (38.9%), and Lianhuan Pharmaceutical (38.6%) leading the gains, while ST Unimed (-18.5%), Shenzhou Cell-U (-13.4%), and Shutai Shen (-11.6%) faced significant losses [11][12]. Industry News and Key Company Announcements - The report outlines several key industry events, including the approval of innovative drugs and strategic partnerships among major pharmaceutical companies, which are expected to enhance their market positions and product offerings [13][16][17]. - The report also mentions significant financial forecasts from various companies, indicating strong growth potential in the sector, with some companies projecting net profit increases of over 100% year-on-year [17][18].

Policy Developments - The National Medical Products Administration (NMPA) is seeking public opinions on the revised procedures for conditional approval of drug listings to improve the review and approval system [2] Drug and Device Approvals - Xuno Pharmaceutical's oral cancer drug, Abexinostat, is proposed for priority review by the NMPA, aimed at adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies [5] - LuKang Pharmaceutical has received the drug registration certificate for Gefitinib tablets, a first-generation targeted drug for non-small cell lung cancer with EGFR gene mutations [6] Capital Market Activities - Shenzhen Keximingde Medical Technology Co., Ltd. completed a multi-hundred million RMB A+ round financing, with funds allocated for brand building and R&D of soft endoscope products [8] - Buchang Pharmaceutical announced the abandonment of the preferential right to acquire shares in its subsidiary, Shaanxi Modern Innovation, resulting in an 86.50% ownership stake post-transfer [9] - Taiji Group plans to optimize its equity structure by acquiring stakes in its subsidiaries for a nominal price [10] Industry Developments - Chugai Pharmaceutical and Gero PTE have signed a $220 million collaboration agreement to integrate Gero's AI-driven platform into Chugai's R&D strategy for developing therapies for age-related diseases [12] - Kanghua Biotech has terminated its collaboration with Xiran Bochuang on the development of mRNA vaccines for tuberculosis, indicating a strategic shift towards in-house R&D capabilities [13] Shareholder Activities - Guizhou Jin Domain Medical Testing Group announced that major shareholder Guochuang Kaiyuan intends to reduce its stake by up to 1% through market transactions [16] - Haichuang Pharmaceutical reported that shareholder Yingchuang Power has cumulatively reduced its stake by 0.28% [17] - Tongrentang announced the resignation of its executive vice president, Zhang Chunyou, who will continue to serve in a managerial role at a subsidiary [18]

Group 1 - Company HaiLu Heavy Industry expects a net profit of 190 million to 205 million yuan for the first half of 2025, representing a year-on-year increase of 48.92% to 60.68% [1] - Company HuaCe Navigation anticipates a net profit of 320 million to 335 million yuan for the first half of 2025, with a year-on-year growth of 38.93% to 46.04% [2] - Company HaoHua Technology projects a net profit of 590 million to 650 million yuan for the first half of 2025, indicating a year-on-year increase of 59.30% to 75.50% [3] Group 2 - Company JiZhi Co. received government subsidies totaling 4.6395 million yuan, accounting for 12.14% of its net profit for 2024 [4] - Company QianYuan Pharmaceutical's subsidiary received approval for the listing of the raw material drug Ebastine, which is used for treating allergic rhinitis and chronic urticaria [5] - Company Anhui Construction won two major engineering projects, with a total estimated investment of 80.85 billion yuan [7] Group 3 - Company FuJian Cement expects a net profit of 20.67 million yuan for the first half of 2025, marking a turnaround from losses [9] - Company LangBo Technology forecasts a net profit of 18 million to 20 million yuan for the first half of 2025, reflecting a year-on-year increase of 49.51% to 66.12% [11] - Company JuHua Co. anticipates a net profit of 1.97 billion to 2.13 billion yuan for the first half of 2025, representing a year-on-year growth of 136% to 155% [13][14] Group 4 - Company Jiangsu Guoxin's subsidiary has officially put into operation a 1 million kilowatt coal-fired power generation unit [15] - Company XiNing Special Steel's controlling shareholder plans to issue up to 578 million shares to raise funds for working capital [16] - Company FengHuo Communication received approval from the CSRC for a stock issuance to specific objects [18] Group 5 - Company WeiLi Medical's subsidiary obtained a medical device registration certificate for a disposable hydrophilic coated visible nasogastric tube [23] - Company ShuGuang Co. reported a 377.22% increase in vehicle production in June, despite a 59.51% drop in sales [24] - Company TaiYang Energy announced a total power generation of 4.159 billion kWh in the first half of 2025, a year-on-year increase of 22.40% [26] Group 6 - Company KeMing Food reported a 111.22% increase in sales revenue from live pigs in June [28] - Company Zhejiang Jiaokao's subsidiaries won contracts for the Hangzhou-Chuzhou Expressway project, totaling over 4.2 billion yuan [30] - Company Huayou Cobalt expects a net profit of 2.6 billion to 2.8 billion yuan for the first half of 2025, reflecting a year-on-year increase of 55.62% to 67.59% [32] Group 7 - Company YingLian Co. anticipates a net profit of 23 million to 28 million yuan for the first half of 2025, with a year-on-year growth of 360.57% to 460.70% [34] - Company DongAn Power expects a net profit of 3.52 million to 5.28 million yuan for the first half of 2025, marking a turnaround from losses [36] - Company RuiSiKangDa's chairman and director are under criminal coercive measures due to alleged information disclosure violations [38] Group 8 - Company ZhouMing Technology's controlling shareholder plans to reduce its stake by up to 1.99% [39] - Company TuoXin Pharmaceutical's subsidiary received approval for the listing of the raw material drug Citicoline [40] - Company TianYu Bio reported a 61.57% increase in live pig sales in June [41] Group 9 - Company WeiNing Health received a government subsidy of 11 million yuan, accounting for 12.52% of its audited net profit for 2024 [42] - Company FuShiLai plans to repurchase shares worth between 20 million and 40 million yuan [43] - Company HuiLong New Materials' controlling shareholder plans to reduce its stake by up to 3% [44] Group 10 - Company DongFeng Co. reported a 20.79% decrease in vehicle production in June [46] - Company BlueSi Technology set the H-share issuance price at 18.18 HKD per share [45] - Company Shanghai XiBa plans to participate in the auction for lithium sulfide business assets with a starting price of 110 million yuan [47] Group 11 - Company ShenNan Electric A expects a net loss of 21 million to 27 million yuan for the first half of 2025 [48] - Company MuYuan Co. reported a 58.35% increase in live pig sales in June [49] - Company BaoTong Technology's controlling shareholder plans to reduce its stake by up to 2.36% [50] Group 12 - Company ZhuoYi Information's employee stock ownership platform plans to reduce its stake by up to 1.88% [51] - Company ChuangWei Digital expects a net profit of 43 million to 63 million yuan for the first half of 2025, a decrease of 65.35% to 76.35% [52] - Company JinLing Mining anticipates a net profit of 133 million to 169 million yuan for the first half of 2025, reflecting a year-on-year increase of 66.48% to 111.54% [53]

药品名称：吉非替尼片 剂型：片剂 包装规格：0.25g 证券代码：600789 证券简称：鲁抗医药 公告编号：2025—032 山东鲁抗医药股份有限公司 关于获得药品注册证书及化学原料药上市申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，山东鲁抗医药股份有限公司（以下简称"公司"）收到国家药品监督 管理局颁发的关于吉非替尼片《药品注册证书》（证书编号：2025S02063）及吉 非替尼原料药《化学原料药上市申请批准通知书》（通知书编号：2025YS00544）。 现将相关情况公告如下： 一、《药品注册证书》基本信息 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 三、药品研发及市场情况 批准文号：国药准字 H20254759 药品标准：YBH15512025 注册分类：化学药品 4 类 生产企业：山东鲁抗医药股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照 ...

Core Viewpoint - LuKang Pharmaceutical (600789) has received the drug registration certificate for Gefitinib tablets and the approval notice for the raw material drug from the National Medical Products Administration, indicating a significant advancement in its oncology product portfolio [1] Company Summary - Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with sensitive EGFR gene mutations [1] - The company has invested approximately 11.1491 million yuan in the research and development of Gefitinib tablets and about 9.9 million yuan in the raw material drug [1] Industry Summary - There are currently 15 existing drug registration numbers for Gefitinib tablets in China, with projected sales of 263 million yuan in 2024 [1]

Core Viewpoint - The company, Shandong Lukang Pharmaceutical Co., Ltd., has shown significant growth in sales revenue and net profit during the reporting period, with a notable increase in sales profit margin attributed to product structure changes and asset disposal gains from land recovery [1][12]. Financial Performance - The company's operating revenue for the reporting periods was 562.14 million yuan, 614.67 million yuan, and 623.31 million yuan, while the net profit attributable to shareholders was 138.01 million yuan, 246.17 million yuan, and 394.62 million yuan, respectively [1][2]. - The sales profit margins were recorded at 2.55%, 4.18%, and 6.55% for the respective years, indicating a steady increase [1][3]. Sales Profit Margin Analysis - The increase in sales profit margin is primarily due to changes in product structure, market competition, and cost variations, with the gross profit margin showing a trend of increase followed by stabilization [2][5]. - The gross profit margins for the reporting periods were 22.19%, 24.65%, and 23.96%, reflecting the impact of product mix and cost management [3][5]. Product Segmentation - The company’s human medicine segment showed a steady increase in gross profit margin for formulation drugs, with margins of 33.68%, 38.02%, and 41.46% over the reporting periods, driven by the introduction of high-margin products and improved production efficiency [5][6]. - The raw material drug segment experienced fluctuations in gross profit margins, with rates of 12.53%, 5.46%, and 8.53%, influenced by market competition and cost changes [10][11]. Export and Revenue Matching - The company’s export revenue showed a strong correlation with customs declaration data, with minor discrepancies deemed reasonable due to small sample exports and internal sales classifications [15][16]. - The total export revenue for the reporting periods was 76.71 million yuan, 78.03 million yuan, and 104.08 million yuan, with the export tax refund amounting to 107.34 million yuan, 69.40 million yuan, and 86.95 million yuan, respectively [16][19]. Market and Competitive Landscape - The company’s external sales were diversified across several countries, including the UK, Netherlands, and Egypt, with stable trade and tariff policies that did not adversely affect export operations [19][20]. - The sales expense ratio for the company was significantly lower than that of comparable companies, recorded at 8.45%, 9.40%, and 9.11% over the reporting periods, reflecting efficient cost management strategies [22][23].

和信会计师事务所（特殊普通合伙） 关于山东鲁抗医药股份有限公司 向特定对象发行股票申请文件的 审核问询函的回复 和信综字（2025）第 000348 号 （修订稿） 二〇二五年七月 和信会计师事务所（特殊普通合伙） 关于山东鲁抗医药股份有限公司 向特定对象发行股票申请文件的 审核问询函的回复 和信综字（2025）第 000348 号 上海证券交易所： 贵所于 2025 年 5 月 9 日出具的上证上审（再融资）〔2025〕137 号《关于山东鲁抗 医药股份有限公司向特定对象发行股票申请文件的审核问询函》（以下简称"问询函"） 已收悉，山东鲁抗医药股份有限公司（简称"鲁抗医药"、"发行人"、"公司"）及我们 对问询函所列问题进行了逐项落实、核查，现对问询函问题回复如下： 如无特别说明，本回复中的简称或名词释义与募集说明书（申报稿）中的相同。本 回复中的字体代表以下含义： 请发行人说明：（1）结合产品结构变化、市场竞争情况、成本变化等，说明报告期 内销售净利率显著增长的原因及合理性，变化趋势与同行业可比公司是否存在显著差异 及合理性；（2）报关数据、出口退税情况与境外收入的匹配性；结合出口国家或地区相 关贸易、关 ...

证券代码：600789 证券简称：鲁抗医药 关于山东鲁抗医药股份有限公司 向特定对象发行股票申请文件的 审核问询函的回复 （修订稿） 保荐机构（主承销商） （北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层） 二〇二五年七月 上海证券交易所： 贵所于 2025 年 5 月 9 日出具的上证上审（再融资）〔2025〕137 号《关于山东鲁抗 医药股份有限公司向特定对象发行股票申请文件的审核问询函》（以下简称"问询函"） 已收悉，山东鲁抗医药股份有限公司（简称"鲁抗医药"、"发行人"、"公司"）、中国国 际金融股份有限公司（简称"保荐机构"、"中金公司"）、和信会计师事务所（特殊普通 合伙）（简称"申报会计师"）、北京市通商律师事务所（简称"发行人律师"）等相关方 对问询函所列问题进行了逐项落实、核查，现对问询函问题回复如下，请予审核。 如无特别说明，本回复中的简称或名词释义与募集说明书（申报稿）中的相同。本 回复中的字体代表以下含义： | 问询函所列问题 | 黑体（不加粗） | | --- | --- | | 对问题的回答 | 宋体（不加粗） | | 对募集说明书等申请文件的修改、补充 | ...